In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates.

Autor: Burke A; University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia; The Prince Charles Hospital, Brisbane, Australia. Electronic address: andrew.burke@health.qld.gov.au., Carter R; Faculty of Medicine, The University of Queensland School of Medicine School of Medicine, Australia; Gallipoli Medical Research Institute, Brisbane, Australia., Tolson C; Gallipoli Medical Research Institute, Brisbane, Australia., Congdon J; Gallipoli Medical Research Institute, Brisbane, Australia., Duplancic C; Faculty of Medicine, The University of Queensland School of Medicine School of Medicine, Australia., Bursle E; Faculty of Medicine, The University of Queensland School of Medicine School of Medicine, Australia; Sullivan and Nicolaides Pathology, Brisbane, Australia., Bell SC; The Prince Charles Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland School of Medicine School of Medicine, Australia; Translational Research Institute, Brisbane, Australia., Roberts JA; University of Queensland Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia; Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia; Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University Hospital, University of Montpellier, Nîmes, France., Thomson R; The Prince Charles Hospital, Brisbane, Australia; Faculty of Medicine, The University of Queensland School of Medicine School of Medicine, Australia; Gallipoli Medical Research Institute, Brisbane, Australia.
Jazyk: angličtina
Zdroj: International journal of antimicrobial agents [Int J Antimicrob Agents] 2023 Oct; Vol. 62 (4), pp. 106938. Date of Electronic Publication: 2023 Jul 28.
DOI: 10.1016/j.ijantimicag.2023.106938
Abstrakt: Objectives: Mycobacterium abscessus is an emerging infection in people living with lung diseases, including cystic fibrosis (CF) and bronchiectasis, and it has limited treatment options and low cure rates. The off-label use of novel antibiotics developed for other bacterial pathogens offers potential new therapeutic options. We aimed to describe the in vitro activity of imipenem, imipenem-relebactam and tedizolid against comparator antibiotics in M. abscessus isolates from Australian patients with and without CF.
Methods: We performed susceptibility testing for imipenem-relebactam, tedizolid and comparator antibiotics by Clinical and Laboratory Standards Institute (CLSI) criteria against 102 clinical M. abscessus isolates, including 46 from people with CF.
Results: In this study, the minimum inhibitory concentration (MICs) of imipenem-relebactam was one-fold dilution less than of imipenem alone. The MIC 50 and MIC 90 of imipenem-relebactam were 8 and 16 mg/L, respectively, whereas for imipenem they were 16 and 32 mg/L. Tedizolid had an MIC 50 and MIC 90 of 2 and 4 mg/L, respectively. Forty non-CF isolates had linezolid susceptibility performed, with MIC 50 and MIC 90 values of 16 and 32 mg/L, respectively, measured.
Conclusions: This study shows lower MICs for imipenem-relebactam and tedizolid compared to other more commonly used antibiotics and supports their consideration in clinical trials for M. abscessus treatment.
(Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: